{"id":"W4387735431","doi":"10.1056/nejmoa2303974","title":"Improved Outcomes with Enzalutamide in Biochemically Recurrent Prostate Cancer","year":2023,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":291,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Calgary; University of British Columbia","funders":"Astellas Pharma US; Pfizer","keywords":"Medicine; Enzalutamide; Prostate cancer; Androgen deprivation therapy; Clinical endpoint; Randomization; Internal medicine; Urology; Placebo; Oncology; Metastasis; Prostate-specific antigen; Combination therapy; Confidence interval; Randomized controlled trial; Surgery; Cancer; Androgen receptor; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000934426,0.0003485734,0.0009715386,0.0002346196,0.0001459168,0.0003462259,0.00026193,0.000275733,0.001157188],"category_scores_gemma":[0.000993063,0.00008934311,0.0005761662,0.0002614823,0.0002771713,0.0002570758,0.0002016186,0.0006259432,0.000157264],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003353271,"about_ca_system_score_gemma":0.0005207068,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005690999,"about_ca_topic_score_gemma":0.001463666,"domain_scores_codex":[0.9996676,0.0001746072,0.00002744418,0.00003634532,0.00004966755,0.00004429994],"domain_scores_gemma":[0.9993995,0.0001211004,0.0002595594,0.00003218957,0.00003853204,0.0001490544],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.4847562,0.009948717,0.07510638,0.001833224,0.002778858,0.0004190906,0.0001884826,0.003510107,0.01928892,0.0001928944,0.002679357,0.3992978],"study_design_scores_gemma":[0.1544832,0.5310902,0.2896548,0.0003767061,0.003908298,0.001681675,0.0001500164,0.003380198,0.008002831,0.0007642532,0.006447302,0.00006047576],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.990599,0.007738681,0.0002036045,0.00023247,0.00004694669,0.000124372,0.0001265921,0.00003043719,0.0008978975],"genre_scores_gemma":[0.9971979,0.001949292,0.0002104663,0.0001349064,0.00004349144,0.00006822871,0.0001700975,0.000003775013,0.0002219789],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001157188,"threshold_uncertainty_score":0.004941761,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02806320405098852,"score_gpt":0.3483904114940708,"score_spread":0.3203272074430823,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}